MedTrace Logo

Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies

NCT01065025 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-04-13

No results posted yet for this study

Summary

The purpose of the study is to investigate safety and tolerability of repeated ascending oral doses of 4SC-205 in patients with advanced and incurable solid tumors or malignant lymphomas.

Conditions

  • Advanced and Incurable Solid Tumors
  • Malignant Lymphomas

Interventions

DRUG

4SC-205

Repeated ascending oral doses of 4SC-205.

Sponsors & Collaborators

  • 4SC AG

    lead INDUSTRY

Principal Investigators

  • Klaus Mross, PD Dr. med. · Klinik für Tumorbiologie an der Albert-Ludwigs-Universität Freiburg (KTB)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01065025 on ClinicalTrials.gov